A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers

2013 ◽  
Vol 54 (5) ◽  
pp. 555-562 ◽  
Author(s):  
Ana Ruiz-Garcia ◽  
Nagdeep Giri ◽  
Robert R. LaBadie ◽  
Grace Ni ◽  
Tanya Boutros ◽  
...  
Keyword(s):  
Single Dose ◽  
Drug Interaction ◽  
Steady State ◽  
Phase I ◽  
Healthy Volunteers ◽  
Potential Drug ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Drug Drug Interaction

scholarly journals Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

2007 ◽  
Vol 51 (8) ◽  
pp. 2982-2984 ◽  
Author(s):  
Mary B. Wire ◽  
Charles H. Ballow ◽  
Julie Borland ◽  
Mark J. Shelton ◽  
Yu Lou ◽  
...  
Keyword(s):  
Steady State ◽  
Healthy Subjects ◽  
Open Label ◽  
Time Curve ◽  
Once Daily ◽  
Open Label Study ◽  
Label Study ◽  
Concentration Time

ABSTRACT Plasma ketoconazole (KETO), amprenavir (APV), and ritonavir (RTV) pharmacokinetics were evaluated in 15 healthy subjects after being treated with KETO at 200 mg once daily (QD), fosamprenavir (FPV)/RTV at 700/100 mg twice daily (BID), and then KETO at 200 mg QD plus FPV/RTV at 700/100 mg BID in this open-label study. The KETO area under the concentration-time curve at steady state was increased 2.69-fold with FPV/RTV. APV exposure was unchanged, and RTV exposure was slightly increased.

Sign in / Sign up

Export Citation Format

Share Document